Browsing by Author "Adam-Artigues, Anna"

Sort by: Order: Results:

  • AXL - a new player in resistance to HER2 blockade
    Adam-Artigues, Anna; Arenas, Enrique J.; Arribas, Joaquín; Prat, Aleix; Cejalvo, Juan Miguel (Elsevier, 2023)
    HER2 is a driver in solid tumors, mainly breast, oesophageal and gastric cancer, through activation of oncogenic signaling pathways such as PI3K or MAPK. HER2 overexpression associates with aggressive disease and poor ...
  • MicroRNA-33b suppresses epithelial-mesenchymal transition repressing the MYC-EZH2 pathway in HER2+ breast carcinoma
    Pattanayak, Birlipta; Garrido Cano, Iris; Adam-Artigues, Anna; Tormo, Eduardo; Pineda, Begoña; Cabello, Paula; Alonso, Elisa; Bermejo, Begoña; Hernando, Cristina; Martínez, María Teresa; Rovira, Ana; Albanell Mestres, Joan; Rojo, Federico; Burgués, Octavio; Cejalvo, Juan M.; Lluch, Ana; Eroles, Pilar (Frontiers, 2020)
    Downregulation of miR-33b has been documented in many types of cancers and is being involved in proliferation, migration, and epithelial-mesenchymal transition (EMT). Furthermore, the enhancer of zeste homolog 2-gene (EZH2) ...
  • miR-146a-5p Promotes angiogenesis and confers Trastuzumab Resistance in HER2+ breast cancer
    Cabello, Paula; Torres-Ruiz, Sandra; Adam-Artigues, Anna; Forés-Martos, Jaume; Martínez, María Teresa; Hernando, Cristina; Zazo, Sandra; Madoz-Gúrpide, Juan; Rovira, Ana; Burgués, Octavio; Rojo, Federico; Albanell Mestres, Joan; Lluch, Ana; Bermejo, Begoña; Cejalvo, Juan Miguel; Eroles, Pilar (MDPI, 2023)
    Trastuzumab treatment has significantly improved the prognosis of HER2-positive breast cancer patients. Despite this, resistance to therapy still remains the main clinical challenge. In order to evaluate the implication ...
  • Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer
    Adam-Artigues, Anna; Rovira Guerín, Ana; Albanell Mestres, Joan; Arribas, Joaquín; Cejalvo, Juan M. (American Association for the Advancement of Science (AAAS), 2022)
    Anti-HER2 therapies have markedly improved prognosis of HER2-positive breast cancer. However, different mechanisms play a role in treatment resistance. Here, we identified AXL overexpression as an essential mechanism of ...
  • The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors
    Tormo, Eduardo; Ballester, Sandra; Adam-Artigues, Anna; Burgués, Octavio; Alonso, Elisa; Bermejo, Begoña; Menendez Romero, Silvia; Zazo, Sandra; Madoz-Gúrpide, Juan; Rovira Guerín, Ana; Albanell Mestres, Joan; Rojo, Federico; Lluch, Ana; Eroles, Pilar (Nature Research, 2019)
    The mechanisms of chemotherapy resistance in triple negative breast cancer remain unclear, and so, new molecules which might mediate this resistance could optimize treatment response. Here we analyzed the involvement of ...
  • The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 gene
    Tormo, Eduardo; Adam-Artigues, Anna; Ballester, Sandra; Pineda, Begoña; Zazo, Sandra; González-Alonso, Paula; Albanell Mestres, Joan; Rovira Guerín, Ana; Rojo, Federico; Lluch, Ana; Eroles, Pilar (Nature Publishing Group, 2017)
    A subset of HER2+ breast cancer patients manifest clinical resistance to trastuzumab. Recently, miR-26a and miR-30b have been identified as trastuzumab response regulators, and their target gene CCNE2 seems to play an ...

Search DSpace

Browse

My Account

In collaboration with Compliant to Partaking